Solubility enhancement of Carvedilol Polymeric Nanoparticles by Nanoprecipitation Technique
International Journal of Drug Delivery Technology · 21.01.2026 · 16 (01)
DOI: 10.25258/ijddt.16.1.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 21.01.2026. Verfasst von Ms. Mallika Tamminana und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Carvedilol is an anticancer drug which is used in treatment of breast cancer. But it has poor water solubility property. The research work is based on improvement of solubility by formulation and development of polymeric nanoparticles by nanoperception technique. HPMCK15M is used as polymer and Polaxmer 407 is used as surfactant. After pre formulation study the drug interaction study is performed by FTIR and DSC analysis. After preparation various evaluation methods are adopted as per the specification. Evaluation method shows F6 formulation produce good entrapment capacity. The result of various kinetic studies is also acceptable. So we concluded that HPMCK15M is the appropriate polymer and Polaxmer 407 is the appropriate surfactant and nanoperception is the best technique to enhance the stability of and able to enhance the anticancer activity
Zitieren
APA
Tamminana, M. M., & Ravikumar, B. (2026). Solubility enhancement of Carvedilol Polymeric Nanoparticles by Nanoprecipitation Technique. International Journal of Drug Delivery Technology, 16(01). https://doi.org/10.25258/ijddt.16.1.52
Vancouver
Tamminana MM, Ravikumar B. Solubility enhancement of Carvedilol Polymeric Nanoparticles by Nanoprecipitation Technique. International Journal of Drug Delivery Technology. 2026;16(01). doi:10.25258/ijddt.16.1.52
BibTeX
@article{Tamminana2026,
author = {Tamminana, Ms. Mallika and Ravikumar, B.V.V.},
title = {Solubility enhancement of Carvedilol Polymeric Nanoparticles by Nanoprecipitation Technique},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {01},
doi = {10.25258/ijddt.16.1.52}
}
EUVIMED